Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase InhibitorMaria Gabriella Brasca, Marina Ciomei, Fulvia Roletto et al.|Journal of Medicinal Chemistry|2009Cited by 128
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Rachele Alzani et al.|Molecular Cancer Therapeutics|2010Cited by 63
Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myelomaClaudia Perrera, Barbara Valsasina, Maurizio Pulici et al.|Cancer Research|2017Cited by 1
294 POSTER Biological characterization of the dual CDK2/TRKA inhibitor PHA-848125Rachele Alzani, C. Mercurio, Clara Albanese et al.|European Journal of Cancer Supplements|2008Cited by 1
Data from Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Rachele Alzani et al.|Unknown|2023Cited by 0